Across TCGA pan-cancer cohorts, RTP2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RTP2 data layer compared with 12 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RTP2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated RTP2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.
BLCA, UCEC, and COAD are the cancer types where RTP2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.